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SAP is an adaptor protein expressed in T cells and natural killer cells. It plays a critical role 
in immunity, as it is mutated in humans with X-linked lymphoproliferative syndrome (XLP), 
a fatal immunodeficiency characterized by an abnormal response to Epstein-Barr virus (EBV) 
infection. SAP interacts with the SLAM family receptors and promotes transduction signal 
events by these receptors through its capacity to recruit and activate the Src kinase FynT. 
Because it has been previously established that FynT is selectively required for the 
development of NKT cells, we examined NKT cells in SAP-deficient mice and in humans with 
XLP. In the absence of SAP, the development of NKT cells is severely impaired both in mice 
and in humans. These results imply that SAP is a potent regulator of NKT cell development. 
They also identify for the first time a defect in NKT cells associated with a human primary 
immunodeficiency, revealing a potential role of NKT cells in the immune response to EBV.
 
SAP (also named SH2D1A) is a small adaptor
protein that is composed of a unique SH2 do-
main with a short COOH-terminal extension.
It is expressed in T cells and NK cells where it
has been found to be essential for the functions
of the SLAM family of immune receptors (1,
2). Through its SH2 domain, SAP associates
with tyrosine-based motifs located in the cyto-
plasmic domain of the SLAM family receptors.
SAP couples these receptors to intracellular sig-
naling pathways by its ability to interact simul-
taneously with the Src-related protein tyrosine
kinase FynT (3). This interaction between SAP
and FynT is direct and involves a second bind-
ing surface in the SH2 domain of SAP and the
SH3 domain of FynT (4). The importance of
SAP in immunity was provided by the finding
that the 
 
SAP
 
/
 
SH2D1A
 
 gene is mutated or de-
leted in humans with X-linked lymphoprolifer-
ative disease (XLP), an inherited fatal immune
dysfunction characterized by a defective immune
response to EBV infection (5). In most of the
cases, affected young boys develop a fulminant
infectious mononucleosis with the features of
a hemophagocytic syndrome. When children
survive this initial episode or are asymptomatic
they go on to develop hypogammaglobunemia
and aggressive lymphoproliferative disorders
such as lymphomas (5). However, the patho-
physiology of XLP remains poorly understood
although studies using SAP-deficient mice
showed that the lack of SAP principally leads to
impaired Th2 cell responses and to a defect in
long-term humoral responses (6–8).
NKT cells represent a peculiar subpopulation
of 
 
   
 
T cells with immunoregulatory properties
by their ability to rapidly secrete large amounts
of cytokines such as IFN-
 
 
 
, IL-4, IL-10, and
TGF-
 
  
 
(9–11). NKT cells express in their ma-
jority an invariant TCR (V
 
 
 
14-J
 
 
 
18/V
 
 
 
8 in
mouse and V
 
 
 
24-J
 
 
 
18/V
 
 
 
11 in humans) that
reacts with the monomorphic MHC class I–like
molecule CD1d. They are also characterized by
expression of receptors of the NK lineage, in-
cluding NK1.1 and NK cell inhibitory receptors.
NKT cells recognized glycolipid antigens pre-
sented by CD1d (9–11). The sponge-derived
glycolipid 
 
 
 
-galactosyl ceramide (
 
 
 
GalCer)
when presented by CD1d selectively activates
NKT cells. In contrast to conventional T cells,
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NKT cells are not subjected to negative selection in the thy-
mus but are positively selected by CD1d expressed on CD4
 
 
 
/
CD8
 
  
 
thymocytes in the presence of the self-glycolipid iGb3
(12, 13). It has been proposed that NKT cells might be im-
portant for the initiation and the regulation of immune re-
sponses by interplaying with innate and adaptive immune re-
sponses (9–11).
There is accumulating evidence supporting the notion that
some of the signaling pathways driving NKT cell development
are unique and differ from those involved in conventional T
cells and NK cells (11). The Src kinase FynT has been shown
to be required for NKT cell development but not for T cell
and NK cell differentiation (14, 15), even though its precise
role in NKT cell ontogeny is not known. Because SAP has the
capacity to associate and to activate FynT (4), we examined
whether SAP is required for NKT cell development. In this
study, we report that the NKT cell development is severely
impaired both in mice and humans lacking SAP. This is the
first report to date describing an inherited fatal immunodefi-
ciency condition in humans in which NKT cells are lacking.
 
RESULTS AND DISCUSSION
Lack of NKT cells in SAP-deficient mice
 
We first examined the amount of NKT cells in the different
hemopoietic organs of SAP-deficient mice by flow cytomet-
ric analysis. The percentages of NKT cells stained by anti-
Figure 1. Defect in NKT cells in SAP-deficient mice. NKT cells were 
analyzed by flow cytometry in the liver, spleen, and thymus of wild-type 
(SAP ), SAP-deficient (SAP ), Fyn-deficient (Fyn   ), and CD1d-deficient 
(CD1d   ) mice. (A) Liver lymphocytes and splenocytes were stained with 
anti-CD19 and thymocytes with anti-HSA. After gating on CD19  or HSAlow 
cells, dot plots were constructed. Representative two-color dot plots show 
staining with anti-TCR  versus anti-NK1.1 antibodies. The percentage of 
NKT cells corresponding to double positive cells in the circle gate is indicated 
in each plot. The data are representative of at least five mice per group. 
(B and C) Absolute numbers of NKT cells in the liver, spleen, and thymus 
mononuclear cells from SAP  (black histogram), SAP  (white histogram), 
and Fyn    mice (gray histogram) stained for NK1.1 and TCR  (B) or NK1.1 
and V 8.2 TCR (C). Cells were counted in each organ and absolute numbers 
of NKT cells were determined based on their proportion (gated on double 
positive cells). Numbers are mean   SD of three mice per group. (D) Same 
experiment as A. Representative two-color dot plots show the staining with 
anti-TCR  antibodies versus  GalCer-loaded CD1d tetramers or unloaded 
CD1d tetramers (right). The percentage of NKT cells corresponding to double 
positive cells in the circle gate is indicated in each plot. The data are repre-
sentative of at least five mice per group. 
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TCR
 
  
 
and anti-NK1.1 antibodies in the liver, spleen, and
thymus of SAP-deficient mice were severely decreased when
compared with wild-type (SAP
 
 
 
) mice (Fig. 1 A). This de-
crease was similar to that found in Fyn-deficient mice (Fig. 1
A). Similar results were obtained with anti-NK1.1 plus anti-
V
 
 
 
8.2 antibodies (not depicted). However, the percentages
of conventional T cells (TCR
 
 
 
  
 
NK1.1
 
 
 
) and NK cells
(TCR
 
 
 
 
 
 
 
NK1.1
 
 
 
) in SAP-deficient and Fyn-deficient mice
were comparable to those observed in wild-type mice (Fig. 1
A). Consistent with the decreased proportions of NKT cells
in SAP-deficient mice, absolute numbers of these cells in the
liver, spleen, and thymus were found to be severely reduced
in SAP-deficient and Fyn-deficient mice relative to wild-
type mice (Fig. 1, B and C). Moreover, very low amounts of
transcripts encoding the V
 
 
 
14-J
 
 
 
18 TCR rearrangement
were detected by semiquantitative RT-PCR in the spleen of
SAP-deficient and Fyn-deficient animals when compared
with wild-type animals (not depicted). Next, we examined
CD1d-restricted NKT cells using CD1d tetramers loaded
with 
 
 
 
GalCer (Fig. 1 D). Although CD1d-restricted NKT
cells were easily detected in wild-type (SAP
 
 
 
) mice, a dra-
matic reduction of their frequency was observed in SAP-
deficient, Fyn-deficient, and CD1d-deficient mice. Impor-
tantly, most of the residual TCR
 
 
 
  
 
 
 
GalCer-loaded CD1d
 
 
 
cells found in SAP-deficient, Fyn-deficient, and CD1d-defi-
cient mice appeared to be nonspecific staining, as a close pro-
portion of these cells were detected with unloaded CD1d
tetramers (Fig. 1 D, right, and not depicted). These data
indicate that SAP-deficient and Fyn-deficient mice lack
CD1d-restricted NKT cells.
NKT cells are known to proliferate and produce IFN-
 
 
 
and IL-4 upon engagement of their invariant TCR with
CD1d-presented 
 
 
 
GalCer (11). Stimulation of wild-type
splenocytes with 
 
 
 
GalCer resulted in a robust cell prolifera-
tion and production of IFN-
 
  
 
and IL-4 (Fig. 2, A–C). By
contrast, no significant cell proliferation and no production
of IFN-
 
  
 
and IL-4 were observed with SAP-deficient and
Fyn-deficient splenocytes cultured in the presence of 
 
 
 
Gal-
Cer (Fig. 2, A–C). As control, stimulation with anti-CD3
plus IL-2 induced a strong cell proliferation by wild-type,
SAP-deficient, and Fyn-deficient splenocytes (Fig. 2 A).
IFN-
 
  
 
production in these conditions was found to be com-
parable between wild-type and SAP-deficient splenocytes,
whereas it was slightly decreased with Fyn-deficient spleno-
cytes. However, SAP-deficient and Fyn-deficient spleno-
cytes failed to produce IL-4 upon anti-CD3 plus IL-2
stimulation. These data were consistent with recent studies
showing that activated T lymphocytes from SAP- and Fyn-
deficient mice have a defect in IL-4 production (6, 16).
Taken together, these results indicate that the compartment
of NKT cells is selectively and severely impaired in the ab-
sence of the SAP protein.
 
Early block in NKT cell development in SAP-deficient mice
 
Next, we examined the developmental steps of NKT cells in
SAP-deficient mice. During their development in the thy-
mus, CD1d-restricted NKT cell precursors primarily acquire
the V
 
 
 
14-J
 
 
 
18/V
 
 
 
8 TCR that allows their subsequent
selection by CD1d-presented self-glycolipid expressed by
CD4
 
  
 
CD8
 
  
 
thymocytes (12, 13). Then, NKT cell precur-
sors up-regulate CD44 and lastly acquire NK1.1 expression
during their final maturation (17). Because CD1d-deficient
mice exhibit a profound defect in NKT cell development
(18), we ascertained that the defect of NKT cells in the ab-
sence of SAP was not caused by a defective CD1d expres-
sion. Expression of CD1d by thymocytes (Fig. 3 A) and
splenic T and B cells (Fig. 3 A and not depicted) in SAP-defi-
cient mice was found to be equivalent to that of wild-type
(SAP
 
 
 
) and Fyn-deficient mice, excluding that a loss of
CD1d expression accounts for the defect of NKT cells ob-
served in SAP-deficient mice. Next, we investigated the ex-
pression of CD44 and NK1.1 by thymocytes of SAP-defi-
cient mice that were positive for 
 
 
 
GalCer-loaded CD1d
tetramers. As shown above in Fig. 1, only a few thymocytes
were positive for 
 
 
 
GalCer-loaded CD1d tetramers in the
SAP-deficient mice in comparison with wild-type (SAP
 
 
 
)
mice. Nonetheless, when examined for CD44 and NK1.1
Figure 2. Absence of  GalCer-dependent NKT cell responses in 
SAP-deficient mice. (A) Proliferation of splenic NKT cells in response to 
 GalCer or anti-CD3 plus IL-2. Splenocytes of wild-type (SAP ), SAP-deficient 
(SAP ), and Fyn-deficient (Fyn   ) mice were cultured at various cell con-
centrations with 100 ng/ml  GalCer or in the presence of 3  g/ml of 
immobilized anti-CD3 antibodies plus IL-2. Proliferation of cells was 
assessed by [3H]thymidine incorporation. Spontaneous proliferation in the 
absence of  Galcer was similar with SAP , SAP , and Fyn    splenocytes. 
Data are presented as a mean   SD of one representative experiment out 
of three. (B and C) IFN-  and IL-4 production by splenic NKT cells (106 sple-
nocytes) in response to  GalCer or anti-CD3 plus IL-2. Cells were stimu-
lated similarly as in A. The presence of IFN-  and IL-4 in the supernatants 
was detected by ELISA. In some cases, IFN-  and IL-4 were not detectable 
(*). Data are from one representative experiment representative of three. 
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expression, most of these residual CD1d tetramer
 
  
 
cells in
SAP-deficient mice did not up-regulate CD44 (94%), and
none of them expressed NK1.1 in contrast to wild-type
(SAP
 
 
 
) cells (0 vs. 31%, respectively; Fig. 3 B). To confirm
the developmental arrest of NKT cells in absence of SAP,
thymocytes from SAP-deficient mice were compared with
those of CD1d-deficient mice. The proportions of residual
CD1d tetramer
 
  
 
cells that are CD44
 
low 
 
were found to be
similar in both mice (94 vs. 93%, respectively; Fig. 3 B), sug-
gesting that the block of NKT cell development occurs at a
related stage in SAP-deficient and CD1d-deficient mice.
Together, these results suggest that the absence of SAP
leads to a severe defect in the early steps of NKT cell develop-
ment before they up-regulate CD44. SAP could be involved
in the intrinsic maturation of NKT cell precursors, the devel-
opment of the thymic microenvironment, or both. However,
we could not strictly exclude that the defect may occur in
more mature cells by activation-induced cell death upon
physiological antigen encounter. It is proposed that the main
function of SAP is to recruit the Src kinase FynT to SLAM
family receptors, allowing their coupling to intracellular path-
ways (19). Thus, one or several members of the SLAM family
receptors might be required for normal NKT cell develop-
ment. Further studies will be needed to test these possibilities.
 
Absence of NKT cells in humans with an XLP
 
Because the lack of SAP is responsible for XLP in humans
(1, 2), we investigated whether NKT cells could be normally
detected in the blood of patients with XLP. XLP patients
carrying different mutations in the 
 
SAP
 
 gene were analyzed
and compared with healthy age-matched individuals as well
as the mother of one patient. None of the XLP patients ex-
cept one (patient 4; see Materials and methods) tested in this
study expressed the SAP protein in his PBLs as shown by
Western blotting of cell lysates performed with anti-SAP an-
tibodies (Fig. 4 B and not depicted). The presence of NKT
cells within the PBLs of an XLP patient (patient 5), his
mother, and a healthy age-matched donor was assessed by
flow cytometry by staining with anti-V
 
 
 
24 TCR and anti-
V
 
 
 
11 TCR antibodies (Fig. 4 A, left) or with anti-V
 
 
 
24
TCR antibodies and 
 
 
 
GalCer-loaded CD1d tetramers (Fig.
4 A, middle). In the PBLs from the healthy individual and
the mother of the XLP patient, NKT cells were significantly
detected with both staining reagents. As a control of specific-
ity, unloaded CD1d tetramers did not identify NKT cells in
the healthy individual nor in the mother of the XLP patient
(Fig. 4 A, right). In striking contrast, no NKT cells were
found in the PBLs of the XLP patient. To confirm this re-
sult, PBLs from three additional patients with XLP and six
healthy age-matched donors were analyzed. The proportion
of NKT cells that were positive for both 
 
 
 
GalCer-loaded
CD1d tetramers and anti-V
 
 
 
24 TCR antibodies ranged
from 0.08 to 0.18% (0.11 
 
  
 
0.04%) in control donors,
whereas no detectable NKT cells were observed in XLP pa-
tients (0.01 
 
  
 
0.01%; P 
 
  
 
0.001; Fig. 4 C). Similar results
were found by using anti-V
 
 
 
24 TCR and anti-V
 
 
 
11 TCR
Figure 3. Impaired NKT cell development in SAP-deficient mice. 
(A) Expression of CD1d on CD4 /CD8  thymocytes (thymus) and spleno-
cytes (spleen) of wild-type (SAP ), SAP-deficient (SAP ), Fyn-deficient 
(Fyn   ) and CD1d-deficient (CD1d   ) mice. After gating on CD4 /CD8  
thymocytes or TCR   splenic cells, histograms corresponding to CD1d 
staining (gray histogram) and isotype-matched irrelevant antibodies (white 
histogram) were constructed. Data are from one experiment representative 
of three. (B) Expression of CD44 and NK1.1 on NKT cell precursors. Thy-
mocytes were stained with anti-NK1.1, anti-CD44, and  GalCer-loaded 
CD1d tetramers. After gating on  GalCer-loaded CD1d tetramer  cells, 
two-color dot plots corresponding to the staining of CD44 and NK1.1 were 
constructed. The percentage of cells in each quadrant is indicated.JEM VOL. 201, March 7, 2005 699
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staining (control donors: 0.18   0.08%, n   8; XLP pa-
tients: 0.00%, n   6; P   0.0002; Fig. 5 A). The six XLP
patients tested had clinical manifestations that were diverse
but typical of XLP (i.e, fulminant mononucleosis, hemo-
phagocytic syndrome, hypogammaglobunemia, and lym-
phoma). Whatever these differences, all XLP patients were
found to have this common lack of NKT cells.
To point out that the absence of NKT cells is restricted
to XLP, we further examined NKT cells from patients af-
fected with other primary immunodeficiencies such as the
closely related inherited hemophagocytic lymphoprolifera-
tive syndromes, the Chédiak-Higashi syndrome (CHS), and
the familial hemophagocytic lymphohistiocytosis syndrome
(FHL; reference 20). In these patients, V 24 /V 11  TCR
NKT cells were significantly detectable (0.09   0.06%, n   3)
compared with XLP patients (0.00%, n   6; P   0.009) and
were found to be similar or slightly reduced relative to
healthy donors (0.18   0.08%, n   8; P   0.12; Fig. 5 A).
Thus, the absence of NKT cells in XLP patients appears to
be specific of this immunodeficiency condition. In addition,
the absence of SAP seems to selectively impair NKT cell de-
velopment because the proportions of NK cells in the PB-
Figure 4. Lack of NKT cells in XLP patients. (A) Representative dot 
plots showing NKT cells in PBLs from an XLP patient (XLP), his mother, and 
an age-matched healthy donor (Control). After gating on CD3  cells, two-
color dot plots showing the staining with anti-V 24 TCR and anti-V 11 
TCR (left) or anti-V 24 TCR antibodies and  GalCer-loaded CD1d tetramers 
(middle) or unloaded CD1d tetramers (right) were constructed. All of the 
cells that were V 24 TCR   GalCer-CD1d tetramer  were also found to be 
V 11 TCR . The percentage of NKT cells (double positive cells) in the circle 
gate is indicated on each dot plot. (B) The absence of SAP protein expression 
in cells from an XLP patient. Cell lysates from the same individuals repre-
sented in A were analyzed by Western blotting with anti-SAP or anti-Fyn 
antibodies as loading controls. (C) Percentage of NKT cells (CD3  V 24 
TCR   GalCer-CD1d tetramer ) in the PBLs of blood samples from four 
patients with XLP (XLP) and six age-matched healthy donors (Ctr.). The 
bars corresponding to the means of percentages are indicated and * indi-
cates P   0.01.
Figure 5. Specificity of the NKT cell defect in XLP. (A) Percentages 
of NKT cells (CD3  V 24 TCR  V 11 TCR ) in the PBLs of blood samples 
from six patients with XLP (XLP) and eight age-matched healthy donors 
(Ctr.) and three patients with CHS and FHL syndromes (Others). (B) Per-
centages of NK cells (CD56 /CD3 ) in the PBMCs of blood samples from 
the same individuals as in A. The bars corresponding to the means of per-
centages are indicated and * indicates P   0.01.REGULATION OF NKT CELL DEVELOPMENT BY SAP | Pasquier et al. 700
MCs of XLP patients (2.9   2.8%, n   6) were comparable
to those observed in patients with other immune defects
(4.0   2.0%, n   3; P   0.55) or in healthy individuals
(4.6   3.6%, n   7; P   0.34; Fig. 5 B). This is consistent
with the normal development of NK cells found in SAP-
deficient mice (Fig. 1).
Altogether, these data indicate that in mice and in hu-
mans, SAP is required for normal NKT cell development.
NKT cells have been proposed to play critical roles in a vari-
ety of immune responses, including host defense against
pathogens, regulation of autoimmunity, and tumor surveil-
lance (10, 11, 21, 22). In this report, we showed that patients
suffering from XLP are devoid of NKT cells, and because
XLP is a severe immunodeficiency characterized by an ex-
treme sensitivity to EBV infection, it is tempting to speculate
that NKT cells may play an essential function in the control
of EBV infection. Future studies should be aimed at address-
ing this important issue.
MATERIALS AND METHODS
Patients. XLP patients have been genotyped for SAP/SH2D1A and were
found to be mutated in SAP resulting in the following amino acid changes
in SAP: SAP X129R (patient 1), SAP R55X (patient 2), SAP E67G (patient
3), and SAP R55P (patient 4). Patient 5 had a deletion of the third exon of
SAP and patient 6 had a single nucleotide insertion causing a frameshift that
leads to a stop codon. The following are the clinical features of the XLP pa-
tients: patient 1 developed hypogammaglobunemia; patients 2, 4, and 6 had
a fulminant infectious mononucleosis with a hemophagocytic syndrome;
and patients 3 and 5 had lymphoma with hypogammaglobunemia. Two
patients with CHS and one patient with FHL who developed hemophago-
cytic syndrome were also analyzed. Ages of the individuals ranged from 1 to
27 yr old for healthy age-matched donors, 4 to 20 yr old for XLP patients,
and 2 mo to 3 yr old for CHS and FHL patients. The mother of patient 5
was 42 yr old. Patients or families provided informed consent for the study
in accordance with the Declaration of Helsinki. This study was approved by
the INSERM Institutional Review Board.
Animals. SAP-deficient (SAP ) mice, Fyn-deficient (Fyn   ) mice, and
CD1d-deficient (CD1d   ) mice have been described elsewhere (15, 23,
24). Male SAP-deficient mice and male wild-type (SAP ) littermates were
typed by PCR. All mice used in this study were from 8 to 11 wk of age.
Mouse studies were performed under the institutional animal care and use
guidelines.
Antibodies and reagents. The following mAbs conjugated to FITC, PE,
APC, or biotin were used: anti-NK1.1 (PK136), anti-TCR  (H57-597),
anti-V 8.1/8.2 TCR (MR5-2), anti-CD4 (RM4-5), anti-CD8 (53-5-8),
anti-CD19 (1D3), anti-CD44 (IM7), anti-HSA (M1/69), and anti-CD1d
(1B1; all from BD Biosciences). PerCP- or PE-conjugated streptavidin
were from BD Biosciences. The mAbs used for experiments in humans
were as follows: anti-V 11 TCR (C21) and anti-V 24 TCR (C15) from
Beckman Coulter and anti-CD3 (SK7) and anti-CD56 (MY31) from BD
Biosciences. CD1d tetramers and  GalCer were provided by A. Bendelac
(University of Chicago, Chicago, IL).  GalCer-loaded CD1d tetramers
were prepared as described previously (24).
Cell preparation and flow cytometry. Single cell suspensions were
prepared from the liver, spleen, and thymus as described previously (14).
Human PBMCs were isolated from blood samples by the standard Ficoll-
Paque method (Axis-Shield PoC AS; Lymphoprep). Murine single cell sus-
pensions or PBMCs were washed twice in PBS containing 2% FCS and
0.1% NaN3 before staining with the indicated reagents. For mouse analysis,
cells were first preincubated with anti-Fc RII/III antibodies (2.4G2) to
block Fc  receptors before staining. Finally, cells were analyzed using a
FACSCalibur and CELLQuest software (Becton Dickinson).
Cell proliferation and cytokine production. Spleen cell suspensions
were incubated in complete medium supplemented or not with 100 ng/ml
 GalCer or stimulated with 3 g/ml of immobilized anti-CD3 (145-2C11)
in the presence of 100 IU/ml of recombinant IL-2. After 36 h in culture,
cells were labeled with [3H]thymidine for 12 h, harvested, and counted in a
microbetaplate counter (Wallac). Supernatants were collected after 48 h of
stimulation with  GalCer and were tested for IL-4 and IFN-  contents by
ELISA according to the manufacturer’s instructions (R&D Systems). All as-
says were performed in duplicate.
Western blot. Immunoblots were performed as described previously (3).
Polyclonal antibodies to human SAP were produced by immunizing rabbits
with a bacterial fusion protein containing the entire human SAP protein.
Semiquantitative RT-PCR. The transcripts encoding the V 14-J 18
TCR rearrangement were detected by RT-PCR. In brief, 5 g of total
RNA was reverse transcripted using random hexamers and Superscript II
reverse transcriptase (Invitrogen), and the cDNAs were amplified by PCR
using specific primers as described previously (18).
Statistical analysis. Student’s t tests were performed with InStat software.
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